<DOC>
	<DOCNO>NCT01167049</DOCNO>
	<brief_summary>To investigate efficacy capecitabine combine paclitaxel neoadjuvant chemotherapy gastric cancer liver metastasis</brief_summary>
	<brief_title>Xeloda Plus Paclitaxel Gastric Cancer With Liver Metastasis</brief_title>
	<detailed_description>Patients advance metastatic gastric cancer poor prognosis . The optimal treatment gastric cancer liver metastases without distant metastasis remain matter debate prospective clinical trial explore area . The aim prospective phase II study evaluate optimal treatment gastric cancer liver metastasis . In preclinical xenograft model , capecitabine highly active several tumor , include breast , colorectal , gastric , cervical tumor , 5-FU-sensitive 5-FU-resistant tumor . Intermittent capecitabine ( 1250 mg/m2 daily dose 14 day , follow 7-day rest period ) show active single agent previously untreated AGC patient , response rate 28.2 % 39 patient . The combination capecitabine drug , cisplatin , oxaliplatin , epirubicin , docetaxel , objective response rate 40-68 % first-line treatment patient AGC . In human colon cancer xenograft model , thymidine phosphorylase upregulated synergy paclitaxel capecitabine observe . The activity capecitabine patient breast cancer refractory paclitaxel anthracyclines suggest combination capecitabine paclitaxel may effective treat patient advance breast cancer . Doses recommended capecitabine 1650 mg/m2 per day orally 14 day paclitaxel 175 mg/m2 i.v . every 3 week . In phase II trial 45 patient involve , 2 patient show complete response 20 show partial response make overall response rate 48.9 % ( 95 % CI:30.3-63.5 % ) . There neutropaenic fever treatment-related death . That study demonstrate paclitaxel capecitabine combination chemotherapy active highly tolerable . The rationale study find outcome could improve neoadjuvant chemotherapy paclitaxel capecitabine without local treatment patient without distant metastasis liver metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Ambulatory male female , age less 18 year . 2 . ECOG performance status : 01 . 3 . Histologically confirm gastric adenocarcinoma . 4 . Radiologically confirm liver metastasis without distant metastasis . 5 . No serious concomitant medical illnesses 6 . Life expectancy 3 month 7 . Be willing able comply protocol duration study 8 . No Prior treatment metastatic disease 9 . Give sign informed consent 1. fit inclusion criterion 2. able comply protocol 3. high risk may compromise benefit propose regimen 4 . Active ( significant uncontrolled ) gastrointestinal bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>gastric cancer liver metastasis</keyword>
</DOC>